8-K: Fortrea Reports Q1 2026 Results, Affirms Guidance

Fortrea Holdings Inc. announced its first quarter 2026 financial results, reporting revenues of $636.5 million and affirming its full-year 2026 guidance.

Summary

• Fortrea Holdings Inc. reported first quarter 2026 revenues of $636.5 million, a slight decrease from $651.3 million in the first quarter of 2025.
• The company reported a GAAP net loss of $23.6 million, or $0.25 per diluted share, an improvement from a GAAP net loss of $562.9 million, or $6.25 per diluted share, in Q1 2025, which included a significant goodwill impairment charge.
• Adjusted net income for Q1 2026 was $15.2 million, or $0.16 per diluted share, up from $1.9 million, or $0.02 per diluted share, in Q1 2025.
• Adjusted EBITDA for the quarter was $47.0 million, an increase from $30.3 million in Q1 2025.
• The book-to-bill ratio for the first quarter was 1.15x, marking the third consecutive quarter above 1.1x, and the trailing 12-month book-to-bill ratio was 1.05x.
• Backlog as of March 31, 2026, stood at $7,846 million.
• Fortrea reaffirmed its full-year 2026 guidance, projecting revenues between $2,550 million and $2,650 million, and adjusted EBITDA between $190 million and $220 million.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive report, with strong operational metrics like the book-to-bill ratio and affirmed guidance, but tempered by a slight revenue decline and continued GAAP net loss.

Positives

• Book-to-bill ratio of 1.15x for the quarter, indicating strong new business wins.
• Third consecutive quarter with a book-to-bill ratio above 1.1x.
• Trailing 12-month book-to-bill ratio of 1.05x.
• Improved GAAP net loss compared to the prior year, largely due to the absence of a significant goodwill impairment charge.
• Significant increase in Adjusted Net Income to $15.2 million from $1.9 million in Q1 2025.
• Substantial increase in Adjusted EBITDA to $47.0 million from $30.3 million in Q1 2025.
• Affirmed full-year 2026 financial guidance, providing visibility and confidence.
• CEO statement highlighting commercial traction and progress on growth and margin expansion.

Negatives

• Revenue decreased to $636.5 million from $651.3 million in the prior year's first quarter.
• Reported a GAAP net loss of $23.6 million for the quarter.
• Free cash flow for the quarter was negative at $(25.0) million.
• Cash and cash equivalents decreased to $147.5 million from $174.6 million at the end of the previous year.

Risks

• Dependence on third parties for critical services.
• Ability to successfully implement business strategies and long-term value creation.
• Risks and expenses associated with international operations, tariffs, trade sanctions, and currency fluctuations.
• Customer or therapeutic area concentrations.
• Risks related to the adoption and benefits of new technology.
• Outcome and impact of pending or future litigation.
• Potential deterioration of the macroeconomic environment, particularly in the pharmaceutical and biotechnology industry.
• Risk that backlog and net new business may not grow as anticipated or be indicative of future revenues.

Future Outlook

Fortrea reiterated its full-year 2026 guidance, expecting revenues to be in the range of $2,550 million to $2,650 million and adjusted EBITDA to be between $190 million and $220 million.

Management Comments

• "We started the year strong, focused on delivering for our clients with excellence and making advances in our strategic journey back to growth and margin expansion," said Anshul Thakral, CEO of Fortrea.
• "Our performance was in line with our expectations for the year, which enables us to invest further in solutions and in our people."
• "Our commercial traction across biotech and large pharma clients underscores we are on the right track."
• "The recent launch of Fortrea Intelligent Technology demonstrates our commitment to outcomes-based innovation that spans the R&D ecosystem."
• "Our collaborative approach and disciplined execution power our progress as a leading CRO."

Industry Context

StockSavvy.ai notes that Fortrea's performance in a competitive CRO market, with a book-to-bill ratio above 1.15x, suggests effective client acquisition and pipeline management, aligning with industry trends focused on outsourcing R&D activities.

Comparison to Industry Standards

• Fortrea's book-to-bill ratio of 1.15x for Q1 2026 is strong, especially when compared to industry averages for CROs which can fluctuate but often aim for ratios around 1.0x to maintain stable growth.
• The company's focus on 'growth and margin expansion' is a key objective for many CROs navigating the post-pandemic landscape, aiming to improve profitability after periods of investment and integration.
• The launch of 'Fortrea Intelligent Technology' reflects a broader industry push towards leveraging data analytics and AI to enhance clinical trial efficiency and outcomes, a trend seen across major players like IQVIA and PPD (now Thermo Fisher Scientific).

Legal Proceedings

• The filing mentions the outcome and impact of pending or future litigation as a risk factor.

Stakeholder Impact

• Shareholders: Reaffirmed guidance provides visibility, but revenue decline and GAAP net loss may be concerns. Improved adjusted metrics are positive.
• Employees: Management's focus on investing in people and strategic journey suggests continued employment opportunities.
• Clients: Strong book-to-bill ratio indicates continued client engagement and trust in Fortrea's services.
• Creditors: Improved adjusted EBITDA and affirmed guidance may provide comfort regarding debt servicing capabilities.

Next Steps

• Host conference call on May 5, 2026, at 8:00 am ET to review Q1 financial results.
• Continue investing in solutions and people.
• Further develop and implement Fortrea Intelligent Technology.
• Focus on growth and margin expansion.

Key Dates

Recommendation

The company demonstrated operational strength with a solid book-to-bill ratio and affirmed guidance, indicating expected performance. However, the slight revenue decline and continued GAAP net loss, alongside negative free cash flow, suggest a cautious approach. A 'hold' recommendation reflects the balance between positive operational momentum and ongoing financial challenges.

Keywords

Fortrea Holdings Inc., Contract Research Organization, CRO, Financial Results, Q1 2026, Revenue, EBITDA, Guidance